AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00457691 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: irinotecan
Description: 180mg/m2 iv day 1 every 14 days
Study NCT00457691 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: levo- leucovorin
Description: 200mg/m2 iv; day 1 every 14 days
Study NCT00457691 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 37.5mg of blinded placebo therapy every day for 28 days followed by 14 days of blinded therapy free period
Study NCT02644239 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: ketogenic diet
Description: Ketogenic diet with high fat (90%)
Study NCT01145248 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: double-balloon enteroscopy forceps biopsy
Description: An endoscopic retrograde cholangiography (ERC) with a duodenoscope Olympus TFJ 160-R (Olympus Corp., Tokyo, Japan) and endoscopic sphincterotomy with an Olympus papillotome (Olympus) is performed under analgosedation . Then, the cannulation of the bile duct is performed by a pusher using a guidewire/guiding catheter. Subsequently, 2 histology samples are taken via a double-balloon enteroscopy (DBE) forceps (BF1725DF, Fujinon GmbH, Willich, Germany), which is placed under the guidance of the pusher.
Study NCT01145248 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transpapillary brush cytology
Description: An endoscopic retrograde cholangiography (ERC) with a duodenoscope Olympus TFJ 160-R (Olympus Corp., Tokyo, Japan) and endoscopic sphincterotomy with an Olympus papillotome (Olympus) is performed under analgosedation . The region of interest is then brushed five times in both directions to obtain cytology specimen.
Study NCT02674750 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CUDC-907
Study NCT00511160 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Myocardial biopsies with TRU CUT 14 Gauge needle
Description: Myocardial needle biopsy and right atrial appendectomy
Study NCT00511160 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endomyocardial biopsies
Description: The control arm C consists of routine-workup of patients with suspected myocarditis, independent of the study arm C, but with analogous screening methods and comparable biopsy sampling
Study NCT00991640 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 2-day preceptorship on obesity management
Study NCT04682847 — intervention group
Intervention type: DRUG
Intervention: Ferumoxytol injection
Description: This is a prospective observation study of 1.5T MR-Linac-SPION imaging with Ferumoxytol for radiotherapy planning in patients with pre-existing liver condition in order to increase safety of liver SBRT with assessment of tumor and hepatic parenchyma response.
Study NCT03955445 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LNP023
Description: LNP023 capsules
Study NCT01282840 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Tolterodine SR
Description: Tolterodine SR 4 mg qd
Study NCT00174434 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SU011248
Description: SU011248 provided as capsules. The starting dose is 25 mg orally, daily in a continuous regimen beginning on day 2. Dose rest for 1 week is allowed. Dose escalation to 37.5 mg po OD is allowed within the constraints of acceptable toxicity parameters. Dosing will continue for 1 year or until disease progression or unacceptable toxicity, whichever comes first.
Study NCT00174434 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel is provided as an intravenous infusion for 1 hour weekly for 3 weeks followed by a 1-week rest. The starting dose is 90 mg/m2. The weekly dose may be decreased to 65 mg/m2 in subsequent cycles based on tolerability. Dosing will continue for 1 year or until maximum benefit, disease progression or unacceptable toxicity, whichever comes first.
Study NCT01334372 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CAMS
Description: First, as discussed above, suicidality is the focus of treatment rather than one of many symptoms being treated. Second is the emphasis on patient and therapist collaborating on treatment rather than the therapist dictating how therapy progresses. Beyond those two basic tenets, each therapist is free to utilize their current clinical skills to conduct psychotherapy.
Study NCT00913978 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Group 1: VitaHeat
Description: Patients will receive active warming via a heating mattress (VitaHEAT Medical) placed on the OR table with two thin sheets between the patient and the device; one covering the mattress and the other used as the draw sheet as usual practice. The device will be turned on 10 minutes prior to the patients' arrival to the operating room table. Patients' upper body will be covered with blankets. To increase skin surface contact with the mattress any blankets remaining under the patients' chest or head will be removed after intubation and replaced with a donut. IV fluid warmer initiated on arrival to the operating room. The operating room temperatures will be adjusted to 21°C.
Study NCT00913978 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Group 2: Bair Hugger
Description: Patients will receive standard forced air warming applied to the upper body and turned on after the patient is prepped and draped. These warmers will be placed directly in contact with the skin without any intervening insulation. IV fluid warmer initiated on arrival to the operating room. The operating room temperatures will be adjusted to 21°C.
Study NCT01977053 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical and psychosocial phone calls
Description: The standard medical supervision is defined as follows:~* Prescription of prophylactics medication (corticoid, antiemetic, cream, mouthwash, etc) at each cycle of chemotherapy.~* Nominative notebook containing details of chemotherapy administered and medical contacts.~* Consultations with psycho-oncologist or psychiatrist (if necessary).~The intervention further comprises: nurse phone calls the 3rd and the 8th day of the first three cycles of treatment, and personalized medical care according to toxicities reported.
Study NCT00626236 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPN-810
Description: capsule taken three times a day
Study NCT00626236 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPN-810
Description: capsule taken TID
Study NCT00042224 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Electroconvulsive Therapy (ECT)
Description: ECT will be used to augment clozapine in schizophrenic patients who continue to have psychotic symptoms despite optimal treatment with clozapine.
Study NCT00042224 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clozapine
Description: Patients with psychotic symptoms will receive clozapine
Study NCT00042224 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clozapine
Description: Patients with psychotic symptoms will receive clozapine
Study NCT04316234 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Passive vape
Description: On days with passive vape, 2-3 vapers in an adjacent chamber were vaping by turn, and vape was passed on to the exposure chamber continuously .
Study NCT01025999 — intervention group
Intervention type: OTHER
Intervention: No intervention
Study NCT02060019 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: administration of exforge 10/160mg for 3days. Next 7days administration of exforge 10/160mg and crestor 20mg.
Study NCT01156935 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laugh Yoga
Description: 1 hour including laugh, respiratory exercises and guided imagination by a group instructor specialized in laugh yoga
Study NCT00563537 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 18F-X PET SCAN
Description: 18F-X PET Scan : Injection of 7.8 mSv for 370 MBq of dose (0.021 mSv / MBq)
Study NCT02101190 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 9-1067
Description: Opicapone, OPC
Study NCT04670419 — intervention group
Intervention type: OTHER
Intervention: Viral clade
Description: Disease outcomes are compared for patients infected with 2 different clades of a HEV gt 3 infection
Study NCT00009646 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: indomethacin
Description: Indocid P.D.A., Merck Frosst, Kirkland, Que., Canada, and Merck, West Point, Pa
Study NCT00009646 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indomethacin
Description: 0.1 mg per kilogram of body weight
Study NCT00009646 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.1 mg per kilogram of body weight
Study NCT03963128 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Supplementation Vitamin D3
Description: Supplementation of vitamin D3 at a dose of 50.000 IU administered every two months (equivalent of 800 IU per day)
Study NCT03963128 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administred every two months
Study NCT04514419 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HS627
Description: Prior to surgery: trastuzumab, HS627, and docetaxel for 4 cycles (1 cycle = 21 days).
Study NCT00115349 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Deferoxamine
Description: Deferoxamine will be given daily for 12-24h/day 7 days a week either subcutaneous or intravenous at up to 50-60 mg/kg/day.
Study NCT00115349 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deferoxamine
Description: Deferoxamine will be given daily for 12-24h/day 7 days a week either subcutaneous or intravenous at up to 50-60 mg/kg/day.
Study NCT02051595 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Vancomycin concentrations
Description: Up to ten blood samples testing for vancomycin concentrations will be collected in subjects administered vancomycin as prophylaxis before cardiac surgery with cardiopulmonary bypass and modified ultrafiltration.
Study NCT04497272 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: COVID-19 patients
Description: It will consist in the collection of 1 additional tubes at their blood draw and 1 urine sample.
Study NCT01838382 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: classic LMA insertion
Description: Classic LMA (cLMA) will be inserted when no response is obtained in the train-of-four stimulation. The fiberoptic view through the LMA, intraoperative complications of the cLMA, any complication during anesthesia emergence will be recorded. The device is examined and noted for the presence of visible blood.
Study NCT01884402 — intervention group
Intervention type: DRUG
Intervention: Peginterferon alfa-2a
Description: Treatment as usual clinical practice
Study NCT01884402 — intervention group
Intervention type: DRUG
Intervention: Ribavirin
Description: Treatment as usual clinical practice
Study NCT00734942 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: support service
Description: * professional partners for communication~* befriending with other families concerned~* information and education (about illness, symptoms, first aid, caring)~* free-time activities and time out~* homework assistance~* administrative advise~* support for everyday life
Study NCT02040311 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topiramate 96 mg daily
Study NCT02040311 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topiramate 192 mg daily
Study NCT02040311 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT04344626 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intra-operative brain tonometry
Description: Once the brain is exposed during surgery, a sterilized digital tonometer will be used to obtain brain tissue stiffness measurements at various locations of the cortex established based on results of pre-operative work-up. Precise stereotactic coordinates for each measurement will be recorded in a neuronavigation software to facilitate comparisons with results of other tests.
Study NCT04532177 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy (SBRT)
Description: fractionated linear accelerator based SBRT to 40 Gy in 5 fractions
Study NCT02580084 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hybrid Intervention
Description: The puncture of the femoral artery general is executed and the introducer 7Fr is set. Further, the hydrophilic conductor executes a recanalization of the Vasa of iliac artery occlusion. if you cannot pass the occlusion retrograde is additional access to antegrade recanalization. Then using hydrophilic conductors, an iliac artery antegrade or retrograde recanalization of the Vasa is made.~Femoral artery arteriotomy. Further execute a direct endarterectomy femoral artery and from the mouth of a hip artery.~arteriotomy of the femoral artery is closed with a vascular patch use (synthetic or biological).~Balloon angioplasty and stenting, iliac artery is done, the controlling angiography Closing maims.
Study NCT02580084 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Aorta femoral Bypass
Description: It is sufficient to identify only the anterior-lateral aorta surface. After heparinization the aorta is clamped above and below the anastomosis. The aorta is dissected along the anterior wall, calcium portions or mural thrombus are removed. Prosthesis is cut obliquely and anastomosis suturing starts with distal angle. Occluded at the prosthetic base jaws, aortic compressor is removed, restoring blood flow in the lower limb. Next stage is tunnel creating for jaws prosthesis conduction on hip. Ureters must remain over the prosthesis, jaw should be above the iliac arteries. After jaws prosthesis conduction on hip distal anastomosis is formed with twisting controlling. Before anastomosis completion the testing jaws and all arteries bloodletting is performed.
Study NCT04769752 — intervention group
Intervention type: OTHER
Intervention: collection of the allocated treatment
Description: collection of the allocated treatment
Study NCT04769752 — intervention group
Intervention type: OTHER
Intervention: collection of medical complications
Description: collection of medical complications
Study NCT01362426 — intervention group
Intervention type: DRUG
Intervention: paliperidone palmitate
Description: Dosage and administration will be according to the paliperidone palmitate approved Australian Product Information.
Study NCT02194023 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo: PCB
Description: Participants were asked to rinse every 12 hours, with 15 ml for 30 seconds, and after spitting to refrain from rinsing their mouths with water and from eating or drinking for at least 60 minutes.
Study NCT02194023 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.12%NF
Description: Participants were asked to rinse every 12 hours, with 15 ml for 30 seconds, and after spitting to refrain from rinsing their mouths with water and from eating or drinking for at least 60 minutes.
Study NCT02194023 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.03%NF
Description: Participants were asked to rinse every 12 hours, with 15 ml for 30 seconds, and after spitting to refrain from rinsing their mouths with water and from eating or drinking for at least 60 minutes.
Study NCT02194023 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PAT
Description: Patients were asked to rinse every 12 hours, and after spitting to refrain from rinsing their mouths with water and from eating or drinking for at least 60 minutes.
Study NCT03063424 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Eucapnic voluntary hyperventilation
Study NCT03063424 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Exercise challenge on a cycle ergometer
Study NCT01884584 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indocyanine green (ICG)
Description: Initial dose of 0.22 mg/kg, which has proven successful in identifying tumor tissue in canine experiments, will be used. The dose will be based on actual body weight. This dose is approximately 40% of the standard human dose for determining cardiac output.
Study NCT03663790 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Foot Progression
Description: The intervention will be a gait retraining biofeedback focused on foot angle during gait trials
Study NCT03663790 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Trunk Lean
Description: The intervention will be a gait retraining biofeedback focused on trunk lean angle during gait trials
Study NCT00497250 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Gefitinib
Description: gefitinib 250 mg/day,PO concurrent with RT and 250 mg/day,PO for 60 days after the completion of RT.
Study NCT00497250 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Radiation Therapy
Description: group 1.54Gy/27Fx concurrent with gefitinib group 2.56Gy/28Fx concurrent with gefitinib group 3.58Gy/29Fx concurrent with gefitinib group 4.60Gy/30Fx concurrent with gefitinib
Study NCT04374799 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Heparin
Description: two doses of heparin
Study NCT04374799 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: placebo
Study NCT03498599 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Novelty facilitated extinction
Description: In the novelty-facilitated extinction design, the aversive outcome (i.e., mild unpleasant electrical pulse) is omitted and replaced by a low volume auditory tone.
Study NCT03498599 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Standard Extinction
Description: During standard fear extinction the expected aversive outcome is omitted.
Study NCT04047537 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Medical Food Formulation 1
Description: WBF-0011
Study NCT04047537 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Medical Food Formulation 2
Description: WBF-0011 (0.2X concentration)
Study NCT04047537 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Placebo
Description: Placebo Capsules identical to those containing Formulation 1 and 2
Study NCT01358149 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: cocoa-based food
Description: single intake of cocoa-based food
Study NCT01358149 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: cocoa-based food
Description: Single intake of cocoa-based food
Study NCT03442959 — intervention group
Intervention type: OTHER
Intervention: Data record
Description: characteristics of patients, initial clinical presentation of TNE, management of TNE (primary tumor resection or conservative strategy), five years follow up (locoregional recurrence, complication due to the surgery, complications related to the conservative strategy, death)
Study NCT04235972 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Follow-up consultation
Description: A follow-up consultation is organized which includes: A clinical examination with standard data collection as well as a face and profile radiograph of the operated wrist.
Study NCT04452695 — intervention group
Intervention type: DEVICE
Intervention: Doctor Spot
Description: Robotic platform (Boston Dynamics) controlled by clinician with video interface to facilitate telemedicine triage
Study NCT04514419 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pertuzumab
Description: Prior to surgery: trastuzumab, Pertuzumab, and docetaxel for 4 cycles (1 cycle = 21 days).
Study NCT00411099 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: agomelatine
Study NCT01033578 — intervention group
Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: PVIC, TACE
Description: PVIC：5-fluorouracil (650 mg/m2 for 24 hours on days 1), doxorubicin (10 mg/m2 for 6 hours on days 2), and cisplatin (20 mg/m2 for 6 hours on days 3) were continuously infused into portal vein through tube by a infusion pump. Treatment started 2 weeks after the operation and was repeated every 4 weeks for 6 cycles.~TACE: 5-fluorouracil (650 mg/m2), doxorubicin (10 mg/m2), cisplatin (20 mg/m2), and lipiodol 5ml were injected into hepatic artery by puncturing the common femoral artery in the right groin and passing a catheter through the abdominal aorta, through the celiac axis and common hepatic artery, into the proper hepatic artery. Treatment started 4 weeks after the operation and was repeated at 6-8 weeks intervals for 3 cycles.
Study NCT01033578 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PVIC, TACE
Description: PVIC：5-fluorouracil (650 mg/m2 for 24 hours on days 1), doxorubicin (10 mg/m2 for 6 hours on days 2), and cisplatin (20 mg/m2 for 6 hours on days 3) were continuously infused into portal vein through tube by a infusion pump. Treatment started 2 weeks after the operation and was repeated every 4 weeks for 6 cycles.~TACE: 5-fluorouracil (650 mg/m2), doxorubicin (10 mg/m2), cisplatin (20 mg/m2), and lipiodol 5ml were injected into hepatic artery by puncturing the common femoral artery in the right groin and passing a catheter through the abdominal aorta, through the celiac axis and common hepatic artery, into the proper hepatic artery. Treatment started 4 weeks after the operation and was repeated at 6-8 weeks intervals for 3 cycles.
Study NCT02722252 — intervention group
Intervention type: DEVICE
Intervention: Embryoscope
Study NCT02722252 — intervention group
Intervention type: DEVICE
Intervention: Embryo culture system without incorporated camera
Study NCT00759720 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-559 and glyburide
Description: TAK-559 16 mg, tablets, orally, once daily and glyburide stable dose orally, once daily for up to 26 weeks.
Study NCT00759720 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-559 and glyburide
Description: TAK-559 32 mg, tablets, orally, once daily and glyburide stable dose, orally, once daily for up to 26 weeks.